Literature DB >> 10758649

[Nerve growth factor auto-antibodies in children with various forms of mental dysontogenesis and in schizophrenia high risk group].

G V Kozlovskaia, T P Kliushnik, A V Goriunova, I L Turkova, M A Kalinina, N S Sergienko.   

Abstract

The level of autoantibodies (AAb) to nerve growth factor was evaluated in blood serum of 163 children with different forms of mental dysontogenesis of endogenic, residual-organic, psychogenic and deprivative origin. Significant elevation of the level of AAb was found in all forms of psychic dysontogenesis. The most significant elevation of the level of AAb (p < 0.01), as compared with the controls (45 children), was characteristic for endogenic forms of dysontogenesis (schizophrenia, early children's autism, schizotypic diathesis). The level of AAb was also found as an indicator of the acuteness of the pathologic state. Besides, its elevation was observed 1-2 weeks prior to the onset of the clinical exacerbation. Elevation of AAb level was also found in psychic dysontogenesis of residual-organic nature (children with perinatal encephalopathy), but it was not so significant as compared with the controls (p < 0.05%). The analysis in the age dynamics of children from this group revealed, that AAb level may serve as some prognostic index of the severity of psychic dysontogenesis. The level of AAb differs some states in schizotypic diathesis and deprivative dysontogenesis, which are clinically quite similar. The method for the estimation of serum AAb level may be proposed as screening in prophylactic medical examination of children from the first year of life under conditions of pediatric outpatient service for identification of risk-groups by psychic dysontogenesis to perform early special psychoprophylaxis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758649

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN: 1997-7298


  7 in total

1.  Differential monocyte responses to TLR ligands in children with autism spectrum disorders.

Authors:  Amanda M Enstrom; Charity E Onore; Judy A Van de Water; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2009-08-08       Impact factor: 7.217

2.  Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes.

Authors:  Paul Ashwood; Amanda Enstrom; Paula Krakowiak; Irva Hertz-Picciotto; Robin L Hansen; Lisa A Croen; Sally Ozonoff; Isaac N Pessah; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

3.  Maternal mid-pregnancy autoantibodies to fetal brain protein: the early markers for autism study.

Authors:  Lisa A Croen; Daniel Braunschweig; Lori Haapanen; Cathleen K Yoshida; Bruce Fireman; Judith K Grether; Martin Kharrazi; Robin L Hansen; Paul Ashwood; Judy Van de Water
Journal:  Biol Psychiatry       Date:  2008-06-20       Impact factor: 13.382

4.  Increased IgG4 levels in children with autism disorder.

Authors:  Amanda Enstrom; Paula Krakowiak; Charity Onore; Isaac N Pessah; Irva Hertz-Picciotto; Robin L Hansen; Judy A Van de Water; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2008-12-25       Impact factor: 7.217

5.  Further characterization of autoantibodies to GABAergic neurons in the central nervous system produced by a subset of children with autism.

Authors:  Sharifia Wills; Christy C Rossi; Jeffrey Bennett; Veronica Martinez-Cerdeño; Paul Ashwood; David G Amaral; Judy Van de Water
Journal:  Mol Autism       Date:  2011-04-26       Impact factor: 7.509

Review 6.  Stem cell therapy for autism.

Authors:  Thomas E Ichim; Fabio Solano; Eduardo Glenn; Frank Morales; Leonard Smith; George Zabrecky; Neil H Riordan
Journal:  J Transl Med       Date:  2007-06-27       Impact factor: 5.531

7.  Proteomic analysis of post mortem brain tissue from autism patients: evidence for opposite changes in prefrontal cortex and cerebellum in synaptic connectivity-related proteins.

Authors:  Jantine Ac Broek; Paul C Guest; Hassan Rahmoune; Sabine Bahn
Journal:  Mol Autism       Date:  2014-07-30       Impact factor: 7.509

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.